Clinical Trials Browser

Phase 1/2 × INDUSTRY × vistusertib × Clear all

NCT03205046 2021-01-06

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

Phase 1/2 Terminated

25 enrolled 11 charts

DLBCL